A Phase III Randomized Study of Satralizumab in Patients with Myasthenia Gravis

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

Principal Investigator(s)
Henry Kaminski, MD
Contact Phone Number
Request Information

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.